Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10502 studies found for:    NCI
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: oblimersen sodium;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Other: laboratory biomarker analysis
2 Completed S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
Conditions: Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
3 Recruiting Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Conditions: Adult B Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Angiofollicular Lymphoid Hyperplasia;   Nodal Marginal Zone Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Plasma Cell Myeloma;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
4 Completed Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: sulindac;   Other: laboratory biomarker analysis
5 Completed Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
Conditions: Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: perifosine;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Completed Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: eribulin mesylate;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study
7 Active, not recruiting
Has Results
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: azacitidine
8 Completed Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: decitabine;   Drug: valproic acid;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Active, not recruiting
Has Results
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions: Adenocarcinoma of the Prostate;   Stage IV Prostate Cancer
Interventions: Drug: cediranib maleate;   Drug: docetaxel;   Drug: prednisone;   Other: laboratory biomarker analysis
10 Completed AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis
11 Completed Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Completed Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: cisplatin;   Drug: dacarbazine;   Procedure: conventional surgery
13 Active, not recruiting Dinaciclib in Treating Patients With Stage III-IV Melanoma
Conditions: Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dinaciclib;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Completed BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
Condition: Sarcoma
Intervention: Drug: rebimastat
15 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Trametinib;   Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis
16 Completed Celecoxib in Treating Patients With Bladder Cancer
Condition: Recurrent Bladder Cancer
Interventions: Drug: celecoxib;   Drug: placebo
17 Recruiting Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: Trebananib;   Biological: Bevacizumab;   Drug: Pazopanib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
18 Recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Lenalidomide;   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis
19 Recruiting Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That Is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Hormone-Resistant Breast Cancer;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Exemestane;   Drug: Entinostat;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
20 Terminated Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Male Breast Cancer;   Stage IV Breast Cancer;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Tumors Metastatic to Brain
Interventions: Drug: cediranib maleate;   Radiation: whole-brain radiation therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years